Sterile Ophthalmic CDMO—Pillar5 Pharma, Inc. provides a competitive edge through various partners as an innovative Contract Development Manufacturing Organization with the vision to be the most competitive & valued sterile ophthalmic & solid dose CDMO competing in the Global Market. Health Canada and FDA approved, offering expertise in sterile ophthalmic, including preservative free (OSD), solid dose, dossiers, and analytical services. With recent sterile expansion, Pillar5 sterile capacity will be doubled in size by 2017. Pillar5 continues to receive the highest quality ranking possible of 100% with major customers. Offering excellence in: operations; quality; business; and customer service providing cost effective solutions to their customers.
James E. Gregory, UPM Pharmaceuticals||October 7, 2015 Pharmaceutical and biopharmaceutical companies large and small are increasingly relying on third-party providers for support at all stages of drug development. To realize efficiencies, they are at the same time reducing the number of suppliers to a preferred few with whom they can form strategic partnerships.
Delana Butz, Ph.D., Manuela Grassi, Ph.D, Onesmo Mpanju, Ph.D., Duu-Gong Wu, Ph.D., Peter Wunderli, Ph.D. , PPD||June 3, 2014 New bioassay methods may help reduce the variability of analytical methods required to demonstrate comparability